Hey team,
Okay, so something just happened in the women's health space that I think is going to be really important for how we think about coaching women over 35.
What's happening: Wisp, a women's telehealth company that's already doing $80M annually, just partnered with a longevity lab to develop peptide therapies specifically for women. They're rolling out injectables, patches, pills, and topicals targeting hormones, inflammation, and metabolism. Using AI to guide prescriptions.
Marketing it as "longevity optimization" for women. And they're not alone. The global peptide market is projected to hit $106B by 2033. Other companies like Midi Health are launching similar female-specific longevity programs.
Here's what this actually means: The same thing that happened with GLP-1s is about to happen with peptides. Except this time, it's specifically targeting women dealing with perimenopause, menopause, and aging. Your female clients are going to start asking about peptides. Probably soon.And honestly? I'm still figuring out how I feel about all this. But I know we need to talk about it.
Let Me Be Honest About Where I'm At With This:
1. I Didn't See This Coming (But I Should Have)
When GLP-1s exploded, I was caught off guard. Clients were asking me about Ozempic and I had no idea what to tell them because I hadn't been paying attention. I promised myself I wouldn't let that happen again. So when I saw this Wisp announcement, my first thought was: here we go again. Another pharmaceutical trend that's going to sweep through my client base, whether I'm ready for it or not.
Peptides have been around in the biohacking and anti-aging communities for years. BPC-157 for injury recovery. Ipamorelin for growth hormone. CJC-1295 for longevity. All this stuff. But it's always been kind of fringe. You'd hear about it from the Dave Asprey types or elite athletes with personal doctors willing to prescribe off-label stuff.
Now it's going mainstream. And specifically, it's being packaged and marketed directly to women as a solution for hormonal issues, metabolic slowdown, and aging. Wisp has 1.5 million patients already. They're growing 70% year over year. When a company of that size starts pushing peptides as part of a "women's longevity stack", that's not fringe anymore.
That's market validation. And if I'm being real? I feel the same mix of skepticism and curiosity I felt when GLP-1s started blowing up. Like, are these things actually going to help my clients? Are they safe? Are they necessary? Or is this just pharmaceutical companies finding another way to medicalize normal aging? I don't have all the answers yet. But I know ignoring it isn't an option.
2. This Is Specifically Targeting Your Female Clients Over 35
Here's what stood out to me: Wisp is explicitly positioning this for women dealing with hormonal changes, menopause, metabolism issues. Not general "anti-aging." Women's longevity specifically. And if you work with women in their 40s, 50s, 60s which most of us do, this is going to be relevant really fast . Because here's what I'm seeing with my female clients in that age range: They're struggling. Perimenopause and menopause are brutal for a lot of women. Energy crashes. Weight gain despite doing everything "right." Sleep issues. Mood swings. Brain fog. Loss of muscle mass. Declining bone density. And traditional medicine has been pretty terrible at helping them. Most doctors just say "that's normal aging" and offer antidepressants or tell them to eat less and exercise more.
